Southern Medicine Institute and Medicine Economic News Office of China Food and Drug Administration jointly released “top 100 pharmaceutical enterprises in China” on June 14. The pharmaceutical business of Fosun Pharma was ranked in the 17th place, much improved compared with 19th place last year.

Top 100 Pharmaceutical Enterprises in China was initiated in 2006 and the activity is held for 7 sessions by this year. The pharmaceutical business of Fosun Pharma has participated in the selection for continuous three years and the ranking is stably improved gradually.

The pharmaceutical industry is core business of Fosun Pharma. With years of emerging and integration, R&D and market promotion, 24 drug R&D and manufacturing enterprises of Fosun Pharma have located 10 provinces, autonomous regions and municipalities directly under the central government all over the country, cover metabolism and digestive canal, angiocarpy, antitumor and immune-regulation, nervous system and anti-infection with key products in leading position in the market. At present, the sales revenues of 13 products exceed 100 million Yuan. Fosun Pharma will further focus on the advantageous resources, develop core pharmaceutical business and improve the competitive capacity of pharmaceutical industry in the future.

Top 100 Pharmaceutical Enterprises in China is selected and organized jointly by Southern Medicine Institute and Medicine Economic News Office of China Food and Drug Administration annually. It is influential in the medicine industry featuring with professionalism, exclusiveness and trueness. In the selection in 2012, the evaluation commission review and sort the pharmaceutical enterprises that are registered in China (excluding branches of international cooperates in China) with pharmaceutical business as core of the operation revenue after concentrated investigation for 5 months, objectively and deeply reflecting the development of leading pharmaceutical enterprises in China.